A provocative overview: epilepsy during pregnancy significantly influences perinatal outcomes, with higher cesarean rates and more small-for-gestational-age (SGA) infants, yet the full picture remains nuanced and shaped by seizure activity and medication choices. Here’s a clear, expanded rewrite that preserves the study’s core findings while making them more accessible for beginners, and invites thoughtful discussion.
Epilepsy frequently presents during reproductive years, and while pregnancy in women with epilepsy (WWE) is often manageable, WWE face higher risks than healthy pregnant women. Research indicates WWE experience about a 0.3–0.7% prevalence in pregnancy, and several studies report increased cesarean section (CS) rates and greater need for obstetric interventions. These differences are not uniform across all populations; ethnicity, geography, and socioeconomic status can worsen obstetric outcomes for WWE.
Data consistently show that WWE pregnancies have markedly higher risks of adverse outcomes: mortality is several times higher, and the likelihood of anemia, premature rupture of membranes, and postpartum hemorrhage is elevated. Effective, individualized care—robust maternal monitoring, precise assessment of illness severity, and timely treatment adjustments—plays a key role in mitigating these risks.
A central factor in outcomes is antiseizure medication (ASM) exposure. Older ASMs, especially valproate, are linked to higher rates of congenital malformations and neurodevelopmental issues in offspring, whereas newer-generation ASMs like levetiracetam and lamotrigine tend to carry lower fetal risk. Consequently, understanding a pregnant WWE’s medication profile is essential when evaluating perinatal outcomes.
Seizures themselves disrupt pregnancy and delivery. Some experts recommend stabilizing seizures before conception, given that seizure patterns can persist into pregnancy, but frequency can still vary during gestation and influence outcomes. Active epilepsy correlates with higher CS rates, partly due to concerns about seizures during delivery and potential complications, which may drive decision-making toward cesarean delivery.
This study investigates the link between maternal epilepsy and adverse perinatal outcomes by comparing WWE to healthy pregnant women. A novel aspect is stratifying WWE by the timing of their last seizure before conception: those whose last seizure occurred within ≤1 year versus >1 year prior. This approach sheds light on how pre-pregnancy seizure control relates to perinatal results, and may guide pre-pregnancy optimization and ongoing prenatal care.
Study design and methods (in plain terms): a retrospective, single-center study at Necmettin Erbakan University Medical Faculty Hospital included 100 WWE and 200 low-risk pregnant controls from 2016–2022. Data were drawn from electronic medical records, including seizure type, ASM use and dosing, seizure timing, and any changes in therapy during pregnancy. Exclusions applied to pregnancies with major fetal anomalies or multiple gestations. Outcomes examined encompassed fetal metrics (birth weight, gestational age at delivery, Apgar scores, small-for-gestational-age status) and maternal outcomes (uterine atony, preeclampsia, hemorrhage, placental abruption, cesarean delivery, transfusions, NICU admissions for newborns, etc.).
Key findings, explained for beginners:
- Cesarean deliveries were more common in WWE (71%) than in controls (55.5%). This aligns with concerns about seizures during labor and physicians’ preference for elective CS in women with uncontrolled epilepsy; overall, WWE still show higher CS rates, though not every study agrees on this point across regions.
- Newborns from WWE tended to have lower birth weight percentiles and higher rates of being small for gestational age (SGA). Specifically, SGA occurred in 28% of WWE versus 12% of controls, signaling a meaningful impact of maternal epilepsy on fetal growth in this cohort.
- WWE mothers experienced longer hospital stays after delivery, indicating greater postpartum care needs and monitoring.
- Seizures during pregnancy occurred in 45% of WWE. Most WWE were on a single ASM (74%), and two-thirds (63%) did not change their ASM regimen during pregnancy.
When examining WWE by seizure presence during pregnancy and by seizure type:
- The presence of seizures during pregnancy markedly increased the CS rate: 91.1% of those who had seizures during pregnancy delivered by CS, compared with 54.5% of those who did not have seizures in pregnancy.
- Predictors of more seizures during pregnancy included having had seizures within the 1 year before conception and having generalized seizures; these relationships were statistically significant, underscoring the importance of achieving a longer seizure-free interval before pregnancy when possible.
- Outcomes between fetal groups (generalized vs non-generalized seizures) were largely similar, with the exception of a lower mean birth weight percentile in the generalized seizure group, a finding that did not translate into higher SGA or NICU admission rates in this study.
Another important angle looked at pre-pregnancy epilepsy experience:
- Women whose last seizure occurred within 1 year before conception had earlier births and lighter newborns than those whose last seizure was more than a year prior, though other serious outcomes did not differ markedly. The cesarean rate was higher in the group with seizures within 1 year before pregnancy.
- Overall, the data suggest that a longer seizure-free period before attempting pregnancy might be associated with better perinatal outcomes, though this observation requires cautious interpretation given the study’s retrospective design.
Additional insights and comparisons:
- The need for cesarean delivery in WWE is not solely due to epilepsy; regional obstetric practices shape CS rates. In this Turkish center, high baseline CS rates in the general population may elevate WWE CS rates regardless of epilepsy status, though WWE still show a higher risk in some comparisons.
- The study’s findings align with some international data showing increased maternal and neonatal morbidity in WWE, including higher rates of CS, preterm birth, and fetal growth restriction. However, other studies have reported no clear adverse outcomes in WWE, highlighting how study design, inclusion/exclusion criteria, and ASM profiles influence results.
Strengths and limitations to keep in mind:
- Strength: The study provides detailed analyses by seizure type, presence of seizures during pregnancy, and the timing of the last pre-pregnancy seizure, enabling nuanced subgroup insights.
- Limitations: It is retrospective and single-center, limiting generalizability. ASM-specific dose levels, polytherapy vs monotherapy, ASM blood levels, and data on fetal anomalies were not extensively analyzed. Some seizures may have been unreported, and long-term neonatal outcomes were not assessed.
Practical takeaways for care teams and patients:
- Preconception counseling matters. If possible, achieving a seizure-free interval of at least one year before pregnancy may be associated with better perinatal outcomes, particularly in terms of birth timing and weight. Clinicians should discuss risks and tailor plans to minimize seizure risk while selecting safer ASM options for fetal health.
- Monitor ASM choice carefully. Where feasible, prefer newer-generation ASMs with more favorable safety profiles, but always weigh maternal seizure control against fetal risk on an individual basis.
- Multidisciplinary care is essential. Obstetricians, neurologists, and perinatal specialists should collaborate to balance seizure control with obstetric safety, plan delivery strategies that minimize seizure risk, and ensure thorough postpartum follow-up.
Controversial angles and prompts for discussion:
- Should the default approach toward elective cesarean in WWE be reconsidered in light of broader regional CS trends and evolving ASM safety data, or is seizure risk during labor a sufficiently strong justification for CS in many cases?
- How aggressively should preconception seizure control be pursued, given that aiming for a long seizure-free interval might delay pregnancy for some individuals, potentially impacting quality of life and family planning?
- With newer ASMs showing safer fetal profiles, to what extent should guidelines push for pre-pregnancy ASM optimization, and how can we ensure equitable access to safer medications across different regions?
In summary, this study reinforces that WWE face higher rates of SGA and CS compared with healthy pregnant women, and that seizure activity before and during pregnancy is a major driver of perinatal outcomes. While epilepsy type alone did not predict most adverse outcomes in this cohort, pre-pregnancy seizure control emerged as a significant factor. These findings advocate for proactive, collaborative, and personalized care for WWE throughout preconception, pregnancy, and postpartum periods, while recognizing the need for prospective, ASM-focused research to refine risk stratification and management.
